A national consensus management pathway for pediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process
Consensus guidance UK for COVID-19 associated multisystem inflammatory syndrome in children
Consent statements represent the views of British doctors. The initial investigation of children with suspected PIMS-TS included blood markers to help determine disease severity, an echocardiogram, and viral and septic screening to rule out other infectious causes.
The importance of a multidisciplinary team in decision making for children with PIMS-TS is highlighted throughout the guide, along with recommended treatment options, including supportive care, intravenous immunoglobulin, methylprednisolone, and biological therapies. 4 September 2020. Lancet. Multisystem inflammatory syndrome in children: A systematic review
- Multisystem inflammatory syndrome in children: a systematic review
- Multisystem inflammatory syndrome is a dangerous and life-threatening new pediatric disease associated with SARS-CoV-2.
This review describes the typical presentation and outcomes in children with this hyperinflammatory condition. Most children will survive thanks to rapid recognition and targeted medical treatment, but the long-term outcomes of this condition are currently unknown. 11 Aug 2020. The Cell. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19
Discovered the mechanism that triggers the inflammatory response in children.
Systemic inflammatory disease caused in children by Sars-Cov2 infection called MIS-C (Multisystem Inflammatory Syndrome in Children) was initially confused with Kawasaki disease. The “CACTUS” study of the Bambino Gesù Pediatric Hospital with the Karolinska Institutet in Stockholm establishes the different immunological characteristics of the two diseases.
In both diseases, Kawasaki and MIS-C, an alteration in the levels of the cytokines involved in the response was detected immune system, but with differences: for example, interleukin 17a (IL-17a) was particularly high in children with Kawasaki disease but not in those with Covid and MIS-C.
The organ damage of patients with Covid who develop MIS-C are due to a high presence of auto-antibodies, ie antibodies directed against particular portions of heart tissue or substances of the body.
- As targeted treatments, researchers suggest the use of high-dose immunoglobulins to limit the effect of autoantibodies, anakinra and cortisone when the disease is at an early stage.
- August 17, 2020. The Lancet Infectious Diseases. COVID-19 and multisystem inflammatory syndrome in children and adolescents
Multisystem inflammatory conditions associated with COVID-19 are often reported in children and adolescents. However, the association between multisystem inflammatory syndrome in children and COVID-19 is still unknown.
A review in The Lancet Infectious Diseases examines the epidemiology, causes, clinical features, and current treatment protocols for COVID-19-associated multisystem inflammatory syndrome in children and adolescents. The review also discusses the possible pathophysiological mechanisms underlying COVID-19-induced inflammatory processes, which can lead to organ damage in critically ill pediatric patients.